Pipeline

Melius is developing two BioPersist product candidates that leverage our GEMM™ technology platform. This first-in-class genetically modified microbial has several potential applications in humans and animals.

Human Product

BP-HUM-001 is the leading drug candidate for BioPersist in humans to treat ulcerative colitis. Few treatments are available for mild-to-moderate colitis patients, as only the safest and most cost-effective drugs and technologies can be developed. Melius is currently preparing to submit an IND application to the FDA for BP-HUM-001 to begin human clinical trials.

Pig Product

BP-POR-001 is the leading product candidate for BioPersist as a feed additive for the pork industry to reduce mortality, improve feed efficiency, and increase weight gain. Melius has already tested BioPersist in pigs, and now aiming to receive clearance for field trials.